title: Update from the Canadian Dyspepsia Working Group.
authors.forename: S J
authors.initials: SJ
authors.lastname: Veldhuyzen van Zanten
authors.forename: N
authors.initials: N
authors.lastname: Flook
authors.forename: N
authors.initials: N
authors.lastname: Chiba
authors.forename: D
authors.initials: D
authors.lastname: Armstrong
authors.forename: A
authors.initials: A
authors.lastname: Barkun
authors.forename: M
authors.initials: M
authors.lastname: Bradette
authors.forename: A
authors.initials: A
authors.lastname: Thomson
authors.forename: F
authors.initials: F
authors.lastname: Bursey
authors.forename: P
authors.initials: P
authors.lastname: Blackshaw
authors.forename: D
authors.initials: D
authors.lastname: Frail
authors.forename: P
authors.initials: P
authors.lastname: Sinclair
mesh_terms: D002170:Canada; D020117:Cisapride / Q000009:adverse effects*; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D005765:Gastrointestinal Agents; D020117:Cisapride